Olema Oncology, Inc.: Janus Henderson Group Ltd. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Janus Henderson Group Ltd. amended its Schedule 13G filing on Olema Oncology, Inc., disclosing a change to its beneficial ownership stake in the company, per SEC accession 0001274173-26-000237. The filing is a passive-investor update, meaning Janus Henderson is not seeking control of the clinical-stage biopharma. The amendment signals a shift in the institutional holder's position, which matters to investors tracking ownership concentration in Olema. Watch for the specific share count and percentage in the amended filing, and whether other large holders follow with their own 13G updates.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Janus Henderson Group Ltd., Olema Oncology, Inc.